Biotech & MedTech News
-
Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies
Coeptis Technologies Signs Binding Letter of Intent to Acquire Key Assets from a Risk Mitigation Software Company with 10,000 customers…
-
Voyageur Announces Closing of First Tranche of Private Placement
December 3, 2024 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (“Voyageur” or the “Corporation”), is pleased…
-
Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries
The Acquisition of NexGenAI Affiliates Network Expands Company’s Capabilities and Drives Innovation, Operational Efficiency, and Opportunity for Growth…
-
Voyageur Announces Extension to Complete Proposed Private Placement
November 26, 2024 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (“Voyageur” or the “Corporation”), is pleased…
-
DIAGNOS Announces Cross-listing of its Common Shares on the Frankfurt Stock Exchange
November 12, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A)…
-
Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development
Study results demonstrate the safety and feasibility of adoptive immunotherapy using allogeneic off-the-shelf NK cells in hospitalized patients…
-
DIAGNOS Announces Closing of Private Placement
October 25, 2024 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use
October 24, 2024 (Source) — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing…
-
DIAGNOS Announces the Engagement of Market Maker Consultant
October 17, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
Voyageur Announces Proposed Private Placement
October 17, 2024 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) (“Voyageur” or the “Corporation”), is pleased to…
